The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | The long-term impact of early lenalidomide treatment on infections and secondary neoplasms in CLL
Kerry Rogers, MD, The Ohio State University, Columbus, OH, discusses an extended follow-up of a Phase II trial (NCT01351896), examining the impact of early lenalidomide treatment (concurrent with the PCV13 pneumococcal conjugate vaccine as opposed to 3 months after the first dose) on disease course, complicating infections, and second neoplasms in patients with high-risk chronic lymphocytic leukemia (CLL). Lenalidomide did not increase the risk of second neoplasms or complicating infections and increased the time to next therapy (TTNT) in this patient population. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Loxo@Lilly, Pharmacyclics, AstraZeneca, Beigene, Janssen, Genentech, AbbVie; Research Funding: Novartis, Genentech, AbbVie.
